Celularity Inc. (CELU) Bundle
A Brief History of Celularity Inc. (CELU)
Foundation and Early Development
Celularity Inc. was founded in 2017, emerging as a biotechnology company focused on developing and commercializing allogeneic cellular therapies for the treatment of diseases. The company was founded by Bob Hariri, who previously co-founded charter companies such as Celgene Cellular Therapeutics.
Initial Funding and Growth Phases
In 2018, Celularity raised $250 million in private equity funding, which helped accelerate its research and development. The company has attracted significant investment from various venture capital firms and strategic partners.
Public Offering
Celularity went public on January 22, 2021, through a merger with Propel Media, Inc., and began trading on the Nasdaq under the ticker symbol CELU. The merger valued the company at approximately $1.1 billion.
Key Products and Clinical Trials
Celularity is primarily known for its innovative therapies that harness the power of placental-derived cells. The leading candidates include:
- CCL-017: A therapeutic candidate in the clinical stage for treating various cancers.
- CCL-019: Focused on immune-mediated diseases.
- Cynata: A partnership for stem cell therapy developments.
The company initiated several clinical trials, including:
- Phase 1 trials for CCL-017 in multiple myeloma and solid tumors.
- Phase 2 trials for CCL-019 targeting Crohn’s disease.
Financial Performance
As of Q2 2023, Celularity reported:
- Revenue: $5 million.
- Net Loss: $23 million.
- Cash and Cash Equivalents: $45 million.
- Total Assets: Approximately $85 million.
Partnerships and Collaborations
Celularity entered collaborations with various institutions, notably:
- University of Pennsylvania: For research on T-cell therapies.
- Novartis: Developing innovative treatment modalities leveraging cellular technology.
| Year | Funding Amount | Valuation at IPO | Revenue | Net Loss |
|---|---|---|---|---|
| 2017 | N/A | N/A | N/A | N/A |
| 2018 | $250 million | N/A | N/A | N/A |
| 2021 | N/A | $1.1 billion | N/A | N/A |
| Q2 2023 | N/A | N/A | $5 million | $23 million |
Market Position and Future Prospects
Celularity currently operates in a competitive landscape alongside major players in the biotechnology sector. With a focus on allogeneic cell therapy, the company is positioned for growth in the regenerative medicine field.
A Who Owns Celularity Inc. (CELU)
Shareholder Structure
The ownership of Celularity Inc. (CELU) can be classified into different categories, including institutional investors, retail investors, and company insiders. As of the latest report, the following table summarizes the current shareholder structure:
| Shareholder Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 40.5% | 25,000,000 |
| Retail Investors | 25.3% | 15,000,000 |
| Company Insiders | 34.2% | 20,000,000 |
Major Institutional Shareholders
Celularity Inc. has several major institutional shareholders that have a significant stake in the company. These include:
| Institution | Number of Shares | Percentage Ownership |
|---|---|---|
| BlackRock, Inc. | 10,000,000 | 16.5% |
| The Vanguard Group, Inc. | 7,500,000 | 12.4% |
| Wellington Management Co. LLP | 5,000,000 | 8.2% |
Executive Officers and Directors
Key executive officers and directors also hold substantial shares of Celularity Inc. The following table lists some of the notable insiders:
| Name | Position | Number of Shares |
|---|---|---|
| Robert Hariri | CEO | 5,000,000 |
| David J. Darnell | Chairman | 4,500,000 |
| Dr. David C. Smith | Chief Scientific Officer | 3,000,000 |
Market Capitalization
The market capitalization of Celularity Inc. represents the total value of its outstanding shares. As of the last close price of $3.00 per share, the total market capitalization is:
Market Capitalization: $180 million
Stock Performance
As of the most recent trading session, Celularity Inc. (CELU) has experienced the following stock performance:
| Metric | Value |
|---|---|
| 52-Week High | $5.00 |
| 52-Week Low | $1.50 |
| Current Price | $3.00 |
| Year-to-Date Performance | +20% |
Recent Financial Data
Financial performance indicators for Celularity Inc. are critical in understanding the company's ownership dynamics. The following table highlights some recent financials:
| Financial Metric | Value (Latest Quarter) |
|---|---|
| Total Revenue | $10 million |
| Net Income | -$5 million |
| Operating Expenses | $15 million |
| Cash and Cash Equivalents | $50 million |
Conclusion
The information presented outlines the diverse ownership structure of Celularity Inc., illustrating the significance of both institutional and insider ownership, alongside the current financial performance metrics that define its standing in the market.
Celularity Inc. (CELU) Mission Statement
Corporate Vision
The mission of Celularity Inc. is encapsulated in its commitment to leveraging the potential of the living cell technology to develop innovative therapies aimed at treating various diseases. Celularity harnesses the power of human placental cells, which can be engineered to tackle conditions including cancer, autoimmune diseases, and other serious health concerns.
Core Values
- Innovation: A relentless pursuit of scientific excellence and technological advancement.
- Integrity: Commitment to ethical practices in research and clinical trials.
- Collaboration: Building partnerships across the healthcare ecosystem to enhance patient care.
- Patient-Centricity: Focused on improving patient outcomes through advanced therapeutic options.
Strategic Goals
Celularity aims to:
- Develop and commercialize cell-based therapies.
- Expand clinical trials for its proprietary products.
- Establish partnerships with pharmaceutical companies.
Financial Overview
As of October 2023, Celularity Inc. reported:
| Financial Metric | Amount (in USD) |
|---|---|
| Market Capitalization | $180 million |
| Revenue (2022) | $5.2 million |
| R&D Expenditure (2022) | $20 million |
| Net Loss (2022) | -$25 million |
| Cash and Cash Equivalents (as of Q3 2023) | $30 million |
Product Pipeline
Celularity’s pipeline includes several advanced therapies, primarily targeting oncology and regenerative medicine:
| Product | Indication | Status | Expected Phase Completion |
|---|---|---|---|
| CELZ-201 | Multiple Myeloma | Phase 2 | Q4 2023 |
| CELZ-301 | Chronic Lymphocytic Leukemia | Phase 1 | Q2 2024 |
| CELZ-401 | Solid Tumors | Preclinical | 2024 |
Commitment to Research and Development
Celularity continues to allocate substantial resources to R&D, with a significant focus on:
- Cell-based immunotherapies
- Stem cell research
- Biomarker discovery
Market Position
As of late 2023, Celularity Inc. remains a compelling player in the cell therapy market, a sector projected to reach $23.5 billion by 2027, growing at a CAGR of 25%.
Conclusion of Mission Statement
Through a rigorous commitment to innovation and excellence, Celularity strives to create revolutionary healthcare solutions that enhance the quality of life for patients globally.
How Celularity Inc. (CELU) Works
Overview of Celularity Inc.
Overview of Celularity Inc.
Celularity Inc. (NASDAQ: CELU) operates in the biotechnology industry, focusing on the development of cell therapies based on placental-derived cells. The company's proprietary technology harnesses the unique capabilities of these cells for therapeutic applications.
Business Model
Celularity’s business model is heavily centered on the development and commercialization of allogeneic cellular therapies. The company targets various disease indications including cancer, immune disorders, and degenerative diseases.
Therapeutic Areas
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Cardiovascular Diseases
Financial Statistics
| Year | Revenue (in millions) | Net Income (in millions) | Total Assets (in millions) | Market Capitalization (in billions) |
|---|---|---|---|---|
| 2020 | $5.2 | -$20.5 | $50.3 | $0.23 |
| 2021 | $8.6 | -$18.2 | $55.1 | $0.30 |
| 2022 | $11.0 | -$15.0 | $61.0 | $0.25 |
| 2023 (Q2) | $9.0 | -$7.5 | $70.0 | $0.28 |
Research and Development
Celularity invests significantly in research and development to advance its cellular therapies. As of 2022, the company allocated approximately $20 million to R&D, focusing on clinical trials and product development.
Clinical Trials
Celularity has several ongoing clinical trials, notably:
- CC-98000 for the treatment of Multiple Myeloma
- CC-11007 for the treatment of COVID-19
- CC-13001 for the treatment of solid tumors
Collaborations and Partnerships
The company has established strategic collaborations with institutions such as:
- UCLA for placental-derived therapies
- Yale University for research on immune modulation
- Novartis for joint research initiatives
Regulatory Environment
Celularity operates under strict regulatory guidelines set by the FDA and other global regulatory bodies for its products, ensuring compliance in clinical trial conduct and product safety.
Stock Performance
As of October 2023, Celularity’s stock (CELU) trades at approximately $1.80 per share, with a year-to-date performance reflecting a -15% change.
Future Outlook
The company aims to expand its product pipeline and plans to initiate new clinical trials in 2024. Expected milestones include:
- Completion of Phase II trials for CC-98000
- Initiation of Phase I trials for CC-13001
- Partnership expansion in Europe and Asia
How Celularity Inc. (CELU) Makes Money
Revenue Streams
Celularity Inc. generates revenue primarily through three main segments: product sales, research collaborations, and grants. These diverse sources help enhance financial stability and growth potential.
Product Sales
Celularity focuses on the commercialization of its proprietary allogeneic cell therapy products. The flagship product, CCL-17, is aimed at treating various cancers and immune-mediated diseases. As of Q3 2023, Celularity reported $3.2 million in product revenue.
Research Collaborations
Partnerships with biopharmaceutical companies and research institutions contribute significantly to revenue. In 2023, Celularity entered into a collaboration with Harvard University for research on placental-derived cells, generating $1.5 million in revenue from upfront payments and milestone achievements.
Grants and Funding
Celularity has also pursued grants for innovative research and product development. In 2023, the company secured a grant of $2 million from the National Institutes of Health (NIH) to support clinical trials for its product pipeline.
Financial Performance
In the most recent financial report for Q3 2023, Celularity showcased the following key figures:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $6.7 million |
| Product Revenue | $3.2 million |
| Research Collaboration Revenue | $1.5 million |
| Grant Revenue | $2 million |
| Net Loss | ($15 million) |
Market Potential
Celularity operates within a rapidly growing market for cell-based therapies. The global cell therapy market is projected to reach $19.9 billion by 2026, indicating a compound annual growth rate (CAGR) of 24.7% from 2021 to 2026.
Cost Structure
Understanding the cost structure is significant for profitability. In Q3 2023, Celularity reported the following operational expenses:
| Expense Category | Amount (USD) |
|---|---|
| Research and Development | $10 million |
| General and Administrative | $5 million |
| Sales and Marketing | $2 million |
| Total Operating Expenses | $17 million |
Future Outlook
Celularity's pipeline includes several product candidates in various stages of development, projected to enhance revenue opportunities as they progress towards clinical trials and potential commercialization. The company aims to initiate Phase 2 clinical trials for CCL-17 targeting solid tumors by late 2024, with an expected market entry in 2026.
Celularity Inc. (CELU) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support